8-K: Current report filing
Published on May 12, 2010
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): May 7,
2010
|
Enzo
Biochem, Inc.
|
|
(Exact
Name of Registrant as Specified in Its Charter)
|
|
New
York
|
|
(State
or Other Jurisdiction of
Incorporation)
|
|
001-09974
|
13-2866202
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
527
Madison Avenue
New
York, New York
|
10022
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
|
(212)
583-0100
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
(Former
Name or Former Address, if Changed Since Last
Report)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Dr.
Christine Fischette, who had been serving as the President of Enzo Therapeutics,
has separated from the Company, and will be pursuing other
interests.
Enzo
continues to develop its therapeutic projects, including its two most advanced
programs, Optiquel™ and Alequel™, and is continuing to seek
partnering opportunities for its all of its clinical activities in line with the
Company's stated objective of repositioning its therapeutics
unit. Enzo believes that this realignment of resources will allow its
Therapeutics unit to contribute more directly to the expansion of its companion
diagnostics efforts.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| ENZO BIOCHEM, INC. | |||
|
Date: May
11, 2010
|
By:
|
/s/ Barry W. Weiner | |
| Barry W. Weiner | |||
|
President
|
|||
3